allodynia semaglutide treatment GLP-1 Drugs: New Reports of Dysesthesia and ⚠️ New Sensory Side Effects

Switching from a compounded vial to an FDA-approved medication is a clinical decision

For instance, individuals who are at risk for metabolic dysfunction but dont yet have full-blown diabetes may benefit from low doses of GLP-1s to prevent the progression of disease

doi: 10.1007/bf00495663 36 MentleinR

The majority of patients using semaglutide for weight loss do not have meaningful insurance coverage for it

In contrast, only 9% want to eat more meat

The temporal association between tirzepatide initiation, progressive constipation, and subsequent obstruction suggests a possible contributory role of GLP-1 RA-induced motility changes, rather than establishing direct causality